Compare Adaptive Biotechnologies Corp (ADPT) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.31 (market cap $4.04B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.92. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | RDTE | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $25.45 | $34.20 |
52-Week Low | $12.30 | $26.40 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
RDTE trades at $29.09, up 1.15% with a bullish technical signal from moving averages. The stock shows consistent dividend activity with multiple payouts in 2026, though key valuation ratios remain unavailable. Technical indicators show neutral oscillators but positive momentum from moving averages, with support and resistance clustered around $29.
The outlook remains mixed with technical strength offset by fundamental data gaps and negative analyst sentiment highlighting structural risks. Investment opportunity exists in the dividend stream, but capital erosion concerns from covered call strategies present significant downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
